CRISPR-based molecular detection uses selected CRISPR-associated proteins to recognize nucleic acid targets and convert that recognition into an analytically detectable response.

Conventional CRISPR genome editing aims to change genetic information in living systems. CRISPR diagnostics instead aims to identify the presence of selected DNA or RNA sequences in a tested sample.

Some Cas enzymes exhibit a useful property: recognition of a matching target can activate cleavage of separate reporter molecules. This activity creates a way to translate molecular recognition into an observable signal.

These technologies are explored in molecular diagnostics, pathogen research, genotyping and biological analysis. Whether a particular assay is suitable for clinical use requires separate validation and applicable regulatory authorization.

A guide RNA helps direct a compatible Cas effector toward a target nucleic acid sequence. In selected systems, successful recognition activates nuclease activity against other accessible single-stranded nucleic acid molecules.

This target-activated cleavage of separate molecules is frequently called collateral cleavage or trans-cleavage. It is distinct from cleavage at the original target sequence.

Diagnostic assay architectures can include reporter molecules that generate a readable signal when cleaved. For example, a reporter can be designed with a fluorophore and a quencher, so separation changes the measured fluorescence.

Reporter cleavage is not universal to every Cas protein. Its presence, substrate preference and activation mechanism depend on the specific effector.

Cas12a is an RNA-guided DNA-targeting effector. In addition to target-directed DNA cleavage, Cas12a can exhibit activated single-stranded DNA cleavage after recognizing a suitable DNA target.

This property was central to the development of DETECTR, an early Cas12-based molecular detection platform.

In classic Cas12 detection designs, the reporter is single-stranded DNA. Recognition of a matching DNA target activates the Cas protein, enabling cleavage of reporter molecules and producing an observable signal.

Not all Cas12 variants recognize identical DNA motifs or exhibit identical reaction characteristics. A system's sensitivity and specificity must be evaluated in its intended molecular context.

Read more about Cas12a recognition in EditGene's CRISPR Technologies page.

Cas13-family effectors are RNA-guided RNA-targeting proteins. Selected Cas13 enzymes exhibit collateral RNA cleavage after recognition of a compatible RNA target.

This property underpinned the original SHERLOCK molecular detection platform, reported by Gootenberg and colleagues in 2017.

In classic Cas13 reporter systems, the sensor recognizes RNA, and an RNA-based reporter serves as the cleavable signal molecule.

Can a Cas13 system detect DNA?

Cas13 is intrinsically associated with RNA recognition, but assay architectures can incorporate preparatory steps that convert information from a DNA target into an RNA molecule accessible to Cas13. The entire assay architecture therefore determines what sample targets can ultimately be reported.

Cas13 proteins differ in their sequence preferences and biochemical behavior. A finding made with one Cas13 subtype should not automatically be generalized to all Cas13 systems.

SHERLOCK and DETECTR are foundational examples of CRISPR-based nucleic acid detection systems. Their classic implementations use different Cas effector families and reporter substrates.

Versions of both platform families have evolved beyond their original configurations. Platform names should therefore not be treated as definitions of one fixed molecular reagent combination.

Biological samples may contain low amounts of the target nucleic acid. Some CRISPR detection platforms therefore integrate nucleic acid amplification to increase the number of target-derived molecules available for detection.

The foundational SHERLOCK and DETECTR demonstrations combined amplification strategies with CRISPR-associated reporter reactions. This contributes to analytical sensitivity under suitable assay conditions.

Amplification and reporter cleavage are separate molecular processes. Their combined performance depends on the sample matrix, molecular specificity and assay design.

Can detection be amplification-free?

Amplification-free CRISPR detection has been explored in research. Such strategies may simplify certain workflows, but sensitivity and practical performance depend strongly on the molecular system and measurement platform.

A claim of high analytical sensitivity in a controlled study cannot automatically be extended to all clinical specimen types.

A CRISPR sensor's molecular activity must be converted into information that an instrument or observer can interpret.

Fluorescence-based detection

A reporter may contain a fluorophore and a quencher. When a compatible reporter is cleaved, their separation can produce an increased optical signal.

Lateral-flow detection

Other assay architectures use reporter molecules compatible with lateral-flow formats. An observable line pattern may communicate an assay result after appropriate processing.

CRISPR-based detection has been explored in multiple areas of nucleic acid testing. These include pathogen-associated sequences, genetic variation and other molecular research questions.

Pathogen-associated nucleic acids

Early SHERLOCK work demonstrated detection of selected viral and bacterial sequences. DETECTR research included identification of human papillomavirus sequences in tested samples.

Genetic variants

Depending on the system, CRISPR recognition can sometimes discriminate closely related nucleic acid sequences. This creates research opportunities for genotyping and variant-associated molecular detection.

Respiratory virus research

In 2020, Broughton and colleagues reported a CRISPR-Cas12 assay for SARS-CoV-2 detection in an evaluated sample setting. Such work helped demonstrate the potential of CRISPR-based molecular testing platforms.

For broader scientific context, visit Research Applications .

Evaluating a CRISPR detection system requires more than observing whether a fluorescent or lateral-flow signal appears.

Analytical performance depends on factors such as target concentration, sequence recognition, background signal, sample matrix and repeatability. Clinical performance, where applicable, requires evaluation in the intended population and use setting.

What are common analytical challenges?

Relevant challenges can include contamination, variable specimen quality, cross-reactive sequences, background reporter cleavage and inconsistencies between analytical and real-world performance.

A sensitive molecular reporter is only one component of a complete validated testing system. Appropriate controls, assay performance characterization and context-specific requirements remain essential.

CRISPR diagnostics demonstrates how RNA-guided molecular recognition can serve a purpose beyond changing genetic information. Selected Cas12 and Cas13 systems can translate target recognition into reporter cleavage and a measurable signal.

The flexibility of these systems has motivated research into portable detection, multiplexing, nucleic acid genotyping and alternative readouts. However, performance remains specific to each assay design and intended application.

Frequently asked questions

Peer-reviewed scientific references

All four diagrams are original conceptual educational graphics linked to scientific publications. They do not reproduce journal figures, laboratory results or clinically validated assay performance.